HLP004
Serotonergic psychedelic
From Wikipedia, the free encyclopedia
HLP004, or HLP-004, also known as deuterated dimethyltryptamine (dDMT) and formerly as CYB004, is a serotonergic psychedelic related to dimethyltryptamine (DMT) which is under development for the treatment of generalized anxiety disorder.[1][5][2][3][4] It is administered by inhalation or intravenous injection.[1][2] The drug is a tryptamine derivative and is a deuterated analogue and form of DMT.[1][5][3]
| Clinical data | |
|---|---|
| Other names | HLP004; HLP-004; CYB004; CYB-004; Deuterated dimethyltryptamine; Deuterated DMT; dDMT |
| Routes of administration | Inhalation, intravenous[1][2] |
| Drug class | Serotonergic psychedelic; Serotonin receptor agonist[1][3] |
| Pharmacokinetic data | |
| Elimination half-life | 37–40 minutes[4] |
| Duration of action | ~40 minutes[4] |
Interactions
Pharmacology
The pharmacodynamic profile of HLP004, including its interactions with serotonin receptors and its effects in animals, is similar to that of DMT.[3] As with DMT, HLP004 is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals.[1][6][3] However, HLP004, due to its deuteration, is more resistant to metabolism than DMT and shows a longer elimination half-life (by 2.5- to 2.9-fold) and slower clearance (by 38 to 55%) in animals.[3] The brain to plasma ratio of HLP004 was also increased (by 30%) relative to DMT, indicating slightly greater central permeability as well.[3]
The pharmacokinetics and effects of HLP004 in humans have been studied and compared with those of DMT.[4] Its elimination half-life was 37 to 40 minutes and its duration was approximately 40 minutes.[4] For comparison, the half-life of DMT in humans has been reported to be 9 to 12 minutes (range 5–19 minutes).[7][8] HLP004 produced more robust psychedelic effects than DMT at lower concentrations.[4]
Chemistry
The exact chemical structure of HLP004 (i.e., which specific hydrogen atoms have been deuterated) does not yet seem to have been disclosed.[1] However, Helus Pharma (formerly Cybin) patented deuterated tryptamines, including deuterated forms of DMT like DMT-d10 (decadeutero-DMT; CAS no. 2742678-60-8), in 2023.[9][10] In addition, DMT-d10 was given the INN deudimethyltryptamine in January 2026.[11] Other deuterated drugs related to HLP004 or DMT-d10 include the deuterated DMT analogue SPL028 (D2-DMT; α,α-dideutero-DMT), the deuterated psilocybin analogue HLP003 (CYB003) (possibly deupsilocin or d10-psilocin), and the deuterated phenethylamine HLP005 (CYB005).[6][2]
Research
As of August 2024, HLP004 is in phase 2 clinical trials for generalized anxiety disorder.[1][5] It was also under development for the treatment of substance-related disorders and of other psychiatric disorders, but development for these indications was discontinued.[1] The drug is under development by Helus Pharma (formerly Cybin).[1][5]